fingolimod

Real risk of rebound syndrome following fingolimod cessation for MS Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs. Source...